{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:02Z","timestamp":1791041282973,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,3]]},"abstract":"Summary<\/jats:title>\n \n Delayed lymphocyte and T\u2010cell immune reconstitution following bendamustine\u2010rituximab (\n BR<\/jats:styled-content>\n ) for indolent non\u2010Hodgkin lymphoma (\n iNHL<\/jats:styled-content>\n ) has been described, but no information is available for chronic lymphocytic leukaemia (\n CLL<\/jats:styled-content>\n ). We present a population\u2010based retrospective analysis of immune reconstitution and risk of infection following\n BR<\/jats:styled-content>\n . Outcomes included timing\/correlates of\n CD<\/jats:styled-content>\n 4+ recovery and risk of \u2265grade 3 infections. Consecutively treated patients (1 April 2014 to 31 January 2017) were included (\n n<\/jats:italic>\n \u00a0=\u00a0295),with a median age of 65\u00a0years (range 33\u201392); 57% were 1st line treatments. Median cumulative bendamustine dose was 1080\u00a0mg\/m\n 2<\/jats:sup>\n (range 140\u20131440\u00a0mg\/m\n 2<\/jats:sup>\n ).\n CD<\/jats:styled-content>\n 4\/\n CD<\/jats:styled-content>\n 8\/\n CD<\/jats:styled-content>\n 19\/\n NK<\/jats:styled-content>\n subsets were available for 148 patients. Median follow\u2010up was 24\u00a0months. Median times to lymphocyte count (\n ALC<\/jats:styled-content>\n ) recovery (\u22651\u00a0\u00d7\u00a010\n 9<\/jats:sup>\n \/l) and\n CD<\/jats:styled-content>\n 4+ recovery (\u22650\u00b72\u00a0\u00d7\u00a010\n 9<\/jats:sup>\n \/l) were 26 and 24\u00a0months, respectively. Bendamustine total dose >1080\u00a0mg\/m\n 2<\/jats:sup>\n (hazard ratio [\n HR<\/jats:styled-content>\n ] 0\u00b74; 95% confidence interval [\n CI<\/jats:styled-content>\n ]: 0\u00b72\u20130\u00b78), end\u2010of\u2010treatment\n ALC<\/jats:styled-content>\n \u22640\u00b74\u00a0\u00d7\u00a010\n 9<\/jats:sup>\n \/l (\n HR<\/jats:styled-content>\n 0\u00b753; 95%\n CI<\/jats:styled-content>\n : 0\u00b73\u20130\u00b79) and\n CD<\/jats:styled-content>\n 4+ <0\u00b71\u00a0\u00d7\u00a010\n 9<\/jats:sup>\n \/l 1\u2010year post\u2010\n BR<\/jats:styled-content>\n (\n HR<\/jats:styled-content>\n 0\u00b703; 95%\n CI<\/jats:styled-content>\n : 0\u00b7008\u20130\u00b715) were covariables for delayed\n CD<\/jats:styled-content>\n 4+ recovery.\n ALC<\/jats:styled-content>\n \u2010recovery \u22651\u00a0\u00d7\u00a010\n 9<\/jats:sup>\n \/l was an unreliable predictor of\n CD<\/jats:styled-content>\n 4+ recovery (negative predictive vale 74%, positive predictive value 86%, likelihood ratio 3\u00b73).\n CD<\/jats:styled-content>\n 4+ lymphopenia >3\u00a0years was a significant risk factor for \u2265grade 3 infections (Odds ratio 3\u00b74; 95%\n CI<\/jats:styled-content>\n : 1\u00b74\u20136\u00b79).\n CD<\/jats:styled-content>\n 4+ recovery after\n BR<\/jats:styled-content>\n is unexpectedly delayed and late recovery is associated with risk of serious infections. Monitoring\n CD<\/jats:styled-content>\n 4+ following\n BR<\/jats:styled-content>\n could identify patients at high risk of delayed infections.\n <\/jats:p>","DOI":"10.1111\/bjh.15722","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T03:39:09Z","timestamp":1544672349000},"page":"957-968","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Kinetics of T\u2010cell subset reconstitution following treatment with bendamustine and rituximab for low\u2010grade lymphoproliferative disease: a population\u2010based analysis"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-9464","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Mart\u00ednez\u2010Calle","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hartley","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ahearne","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kasenda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Department of Haematology University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Beech","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Balotis","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wagner","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"Ernest and Helen Scott Haematological Research Institute University of Leicester Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Miall","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-1036","authenticated-orcid":false,"given":"Mark","family":"Bishton","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9254","authenticated-orcid":false,"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0079"},{"key":"e_1_2_8_4_1","first-page":"96","article-title":"Abstract 032: immunochemotherapy with bendamustine\u2010rituximab (Br) as induction therapy for indolent lymphomas results in a severe lymphopenia with low Cd4+ and Cd8+ counts without an increase in atypical infections. (Stil Nhl 7\u20132008)","volume":"31","author":"Burchardt A.","year":"2013","journal-title":"Hematological Oncology"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3041"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090675"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.921298"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_8_15_1","volume-title":"Holland\u2010Frei Cancer Medicine","author":"Kufe D.W.","year":"2003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2112-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.18-1-10"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-3-223"},{"key":"e_1_2_8_20_1","unstructured":"MHRA. (2017).Drug Safety UpdateVolume 10 Issue 11 July 2017: 2. Medicines and Healthcare Products Regulatory Agency.https:\/\/www.gov.uk\/drug-safety-update\/bendamustine-levact\u2010 increased\u2010mortality\u2010observed\u2010in\u2010recent\u2010clinical\u2010studies\u2010in\u2010off\u2010label\u2010use\u2010 monitor\u2010for\u2010opportunistic\u2010infections\u2010hepatitis\u2010b\u2010reactivation."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2178-9"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2\u2010chlorodeoxyadenosine induces durable remissions and prolonged suppression of Cd4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour J.F.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.89"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1026818"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15722","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:30:37Z","timestamp":1694694637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bjh.15722"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15722","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"2018-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}